SCHEMBL3008907

SCHEMBL3008907

Cc1ccc(C)c(-c2csc(N3CCN(S(=O)(=O)c4cccc(Cl)c4Cl)CC3)n2)c1

nearest known ligand 0.56

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
AR P10275 3/20 0.56
ALDH1A1 P00352 4/20 0.49
MAPT P10636 3/20 0.49
LMNA P02545 3/20 0.49
KMT2A Q03164 3/20 0.49
SMN1; SMN2 Q16637 3/20 0.49
MEN1 O00255 2/20 0.49
TP53 P04637 1/20 0.45
L3MBTL1 Q9Y468 2/20 0.43
MAPK1 P28482 2/20 0.43
RAB9A P51151 1/20 0.43
NFKB1 P19838 1/20 0.43
NFKB2 Q00653 1/20 0.43
RELA Q04206 1/20 0.43
TSHR P16473 1/20 0.43
USP2 O75604 1/20 0.42
RECQL P46063 1/20 0.42
HSD17B10 Q99714 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2999125 0.92 AR (0.58) ARALDH1A1MAPTLMNAKMT2A
SCHEMBL3010819 0.89 KMT2A (0.52) ARALDH1A1MAPTLMNAKMT2A
SCHEMBL3016263 0.86 LMNA (0.48) ARALDH1A1MAPTLMNAKMT2A
SCHEMBL3008326 0.86 LMNA (0.48) ARALDH1A1MAPTLMNAKMT2A
SCHEMBL3011207 0.86 MAPT (0.53) ARALDH1A1MAPTLMNAKMT2A
SCHEMBL3001137 0.86 AR (0.58) ARALDH1A1MAPTLMNAKMT2A
SCHEMBL3011439 0.86 LMNA (0.60) ARALDH1A1MAPTLMNAKMT2A
SCHEMBL3004509 0.86 AR (0.53) ARALDH1A1MAPTLMNAKMT2A
SCHEMBL3020238 0.85 MAPT (0.55) ARALDH1A1MAPTLMNAKMT2A
SCHEMBL3002410 0.85 AR (0.57) ARALDH1A1MAPTLMNAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA AR 3801/4885ALDH1A1 3510/4885MAPT 18/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.